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Abstract: Hyperoside is a major active constituent in many medicinal plants which are 
traditionally used in Chinese medicines for their neuroprotective, anti-inflammatory and 
antioxidative effects. The molecular mechanisms underlying these effects are unknown.  
In this study, quiescent ECV304 cells were treated in vitro with advanced glycation end 
products (AGEs) in the presence or absence of hyperoside. The results demonstrated that 
AGEs induced c-Jun N-terminal kinases (JNK) activation and apoptosis in ECV304 cells. 
Hyperoside inhibited these effects and promoted ECV304 cell proliferation. Furthermore, 
hyperoside significantly inhibited RAGE expression in AGE-stimulated ECV304 cells, 
whereas knockdown of RAGE inhibited AGE-induced JNK activation. These results 
suggested that AGEs may promote JNK activation, leading to viability inhibition of 
ECV304 cells via the RAGE signaling pathway. These effects could be inhibited by 
hyperoside. Our findings suggest a novel role for hyperoside in the treatment and prevention 
of diabetes. 
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1. Introduction 
Hyperoside is a flavonoid compound mainly found in herbal plants which are traditionally used in 
Chinese medicines for their neuroprotective, anti-inflammatory, antioxidative and vascular protective 
effects. However, the molecular mechanism underlying these actions is unknown. 
Endothelial dysfunction is a key triggering event in atherosclerosis. Treatment with hyperoside has 
been found to attenuate endothelial cell damage induced by oxidative stress [1]. Some studies have 
shown that hyperoside significantly decreases total cholesterol, triglyceride, low density lipoprotein and 
very low density lipoprotein levels in serum, coupled with elevation of high density lipoprotein in 
diabetic rats [2]. 
The binding of advanced glycation end products (AGE) to the receptor for AGE (RAGE) is known to 
deteriorate various cell functions and is implicated in the pathogenesis of diabetic vascular 
complications [3]. AGEs activate the RAGE gene through NF-kappaB (NF-κB) and Sp-1 in ECV304 
cells, thereby enhancing AGE-RAGE interactions, which can lead to an exacerbation of diabetic 
microvasculopathy [4]. It is unclear whether hyperoside can inhibit apoptosis in ECV304 cells in 
response to AGEs. 
We hypothesized that RAGE could mediate the intracellular signals in ECV304 cells initiated by 
AGEs, resulting in activation of the c-Jun N-terminal kinases (JNK) pathway and apoptosis in ECV304 
cells. Our findings indicated that hyperoside may inhibit JNK activation and promote ECV304 cell 
proliferation by downregulating RAGE. 
2. Results and Discussion 
2.1. Hyperoside Promotes Cell Viability and Attenuates the Effects of AGEs (MTT) 
It has been reported that AGE inhibits proliferation of ECV304 cells [5,6]. However, it is unknown 
whether hyperoside can inhibit these effects. A significant difference in cell viability between the 
AGE-treated and negative control (NC) groups was observed (p < 0.01), indicating that treatment with 
AGEs could inhibit cell viability in ECV304 cells. In contrast, there was a significant difference between 
cells treated with AGEs and hyperoside compared to those treated with AGEs alone (p < 0.05; Figure 1), 
indicating that hyperoside promoted cell viability. 
2.2. Hyperoside Inhibits AGE-Induced Activation of JNK in ECV304 Cells 
To date, there are no data available on the effects of hyperoside in AGE-induced activation of JNK in 
ECV304 cells. P-JNK is the activated JNK. When JNK was activated by some kinds of stimulations, 
more P-JNK can be detected. As shown by Western blot analysis (Figure 2), the increase in JNK 
activation induced by AGEs was significantly inhibited by hyperoside in ECV304 cells (p < 0.05). This 
suggests that hyperoside may have an inhibitory effect on JNK activation. Int. J. Mol. Sci. 2013, 14  22699 
 
Figure 1. Hyperoside promotes cell viability and attenuates the effects of advanced 
glycation end products (AGEs). Cells were seeded in 96-well culture plates. After incubation 
at 37 °C for 24 h, the medium was replaced with fresh medium supplemented either with or 
without hyperoside (50 μg/mL). After incubation for a further hour, AGEs (200 μg/mL) 
were added to the cells for 10 min. The viability of ECV304 cells were detected after 24 h 
treatment with AGEs, either in the absence or presence of hyperoside. The results are shown 
as a percentage of negative control. (a) AGEs vs. NC (p < 0.01); (b) AGEs + H vs. AGEs  
(p < 0.05). NC, negative control; H, hyperoside. 
 
Figure 2. Hyperoside inhibits AGE-induced activation of JNK in ECV304 cells.   
(A) Western blotting shows the activation of c-Jun N-terminal kinases (JNK) (P-JNK) in 
ECV304 cells in response to AGEs in the absence or presence of hyperoside; (B) The 
statistical results of (A) show (a) vs. NC (p < 0.05); and (b) AGEs + H vs. AGEs (p < 0.05). 
Results are from three independent experiments; β-actin was used as an internal control.  
NC, negative control; H, hyperoside. 
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2.3. Hyperoside Downregulates AGE-Induced Expression of RAGE in ECV304 Cells 
In order to determine whether hyperoside affected RAGE expression induced by AGEs, quiescent 
ECV304 cells were treated with AGEs either with or without hyperoside. As shown by real time qPCR 
and Western blot analysis (Figure 3), in the absence of hyperoside AGEs significantly increased 
expression of RAGE relative to negative control (p < 0.05). In contrast, this effect was significantly 
inhibited by hyperoside (p < 0.05). These results suggest that AGEs may induce upregulation of RAGE 
and that this effect can be inhibited by hyperoside. 
Figure 3. Hyperoside downregulates expression of RAGE induced by AGEs in ECV304 
cell. (A) qPCR shows the expression levels of RAGE in ECV304 cells treated by AGEs in 
the absence or presence of hyperoside. (*) vs. NC (p < 0.05); and (
#) AGEs + H vs. AGEs  
(p < 0.05); (B) Western blotting shows the expression levels of RAGE in ECV304 cells 
treated by AGEs in the absence or presence of hyperoside; (C) The statistical results of  
(B) show (a) vs. NC (p < 0.05); and (b) AGEs + H vs. AGEs (p < 0.05). Results are from 
three independent experiments; β-actin was used as an internal control. NC, negative 
control; H, hyperoside. 
 
2.4. Knockdown of RAGE Inhibits AGE-Induced Activation of JNK in ECV304 Cells 
To further assess the contribution of RAGE to AGE-induced activation of JNK, quiescent ECV304 
cells transfected with siRNA-RAGE were treated with AGEs either with or without hyperoside.  Int. J. Mol. Sci. 2013, 14  22701 
 
As shown by Western blot analysis (Figure 4), activation of JNK in ECV304 cells was significantly 
inhibited by knockdown of RAGE relative to a control group (p < 0.05). These results suggest that 
RAGE may mediate JNK signaling induced by AGEs. 
Figure 4. Knockdown of the receptor for AGE (RAGE) inhibits AGE-induced activation of 
JNK in ECV304 cells. (A) Western blotting shows the effect of siRNA-RAGE on 
expression of RAGE; (C) Western blotting shows that knockdown of RAGE  via 
siRNA-RAGE results in significant inhibition of JNK activation induced by AGEs;  
(B,D) The statistical results of (A) and (C) show (*) siRNA-RAGE (SIR-Rage) vs. siRNA 
control (Sir-Ctrl); AGEs vs. (a) Lipofectamine 2000 control (Lipo); (b) Non-targeting siRNA 
control (Sir-Ctrl); and (c,d) siRNA-RAGE (SIR-Rage) or Sir-Ctrl. All results gave p < 0.05. 
Results are from three independent experiments; β-actin was used as an internal control. 
 
2.5. Discussion 
Human cell line ECV304, derived from urinary bladder carcinoma, showed some biomarkers 
expected of endothelial cell lines, namely Factor VIII, tubule formation on Matrigel, and/or 
Weibel-Palade bodies, and so ECV304 cells were selected to study the functions of endothelium cells. 
RAGE belongs to the immunoglobulin superfamily of cell surface molecules [7]. It is expressed in 
multiple tissues [8] and interacts with various ligands including AGE [9,10]. The engagement of RAGE 
by AGEs has been reported to induce cellular oxidant stress via activation of the transcription factor Int. J. Mol. Sci. 2013, 14  22702 
 
nuclear factor-κB (NF-κB) [11,12], which evokes inflammatory and thrombogenic responses in various 
types of cells, including endothelial cells, smooth muscle cells, macrophages and renal cells, leading to 
the perturbation of a variety of vascular homeostatic functions. AGEs impair cell functions, such as 
proliferation, migration, apoptosis and adhesion. Abnormal proliferation and migration of these cells 
directly increase the thickness of the intima and accelerate the formation of atherosclerotic plaque. On the 
contrary, abnormal apoptosis of these cells leads to rupture of plaque. As such, the AGE-RAGE interaction 
is thought to play a central role in the development and progression of diabetic vasculopathy [4]. 
RAGE can engage with AGEs, thereby promoting activation of JNK (Figure 2). It is widely known 
that activation of JNK is an important step in the induction of cell apoptosis. Finally, a decrease in  
cell viability was observed (Figure 1). At the same time, in agreement with Tanaka et al. [4] and  
Shi L. et al. [13], our results confirmed that AGEs can induce upregulation of RAGE in ECV304 cells 
(Figure 3), which maybe promote cell apoptosis by the AGEs/RAGE/JNK pathway, because there is 
more RAGE that can engage with AGEs. In contrast, knockdown of RAGE expression with 
siRNA-RAGE significantly inhibited AGE-induced JNK activation in ECV304 cells (Figure 4). These 
results suggested that AGEs may play an important role in the genesis and progression of atherosclerosis 
via the RAGE/JNK signaling pathway. 
The expression of vascular RAGE can be inhibited by clinical drugs and compounds. These include 
antihypertensive drugs (Telmisartan [14] and Candesartan [15]), vitamin A [16], selenium [17], n-3 
polyunsaturated fatty acids [18], antihyperlipidemic agents (statins) [19], antidiabetic agents 
(thiazolidinediones) [20], peroxisome proliferator-activated receptor gamma [21] and several extracts 
from Chinese traditional medicines, such as ginkgo biloba extract [22] and Panax notoginseng  
saponins (PNS) [23]. This suggests that reduced expression of RAGE may contribute to the therapeutic 
value of these drugs. 
Hyperoside is widely used in clinical practice to relieve pain and improve cardiovascular functions. It 
can protect cortical neurons from oxygen-glucose deprivation-reperfusion induced injury via the nitric 
oxide signaling pathway and the extracellular signal-regulated kinases (ERK), JNK and Bcl-2 
family-related apoptotic signaling pathways [24]. In this study, hyperoside was found to suppress RAGE 
expression, resulting in a significant decrease in AGE-induced activation of JNK to promote 
proliferation in ECV304 cells (Figures 1–3). These results outline a new mechanism of the pleiotropic 
effects of hyperoside in ECV304 cell proliferation in response to AGEs. 
3. Materials and Methods 
3.1. ECV304 Cell Culture 
Human cell line ECV304, derived from urinary bladder carcinoma was purchased from the Shanghai 
Institute of Cell Biology (SIBCB; Shanghai Institutes for Biological Sciences, Chinese Academy of 
Sciences, Shanghai, China). The cells were cultured in RPMI 1640 (Life Technologies, Carlsbad, CA, 
USA) supplemented with 10% fetal calf serum, penicillin and streptomycin at 37 °C in a humidified 
atmosphere of 5% CO2. The medium was changed every 2 days and the cells were passage by treatment 
with 0.05% trypsin-0.02% EDTA. Experiments were performed on ECV304 cells at the point  
of confluence. 
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3.2. AGE Preparation 
AGEs were prepared in a manner similar to that described by Kim et al. [25]. Briefly, 1 mM fatty 
acid-free bovine serum albumin (BSA) was dissolved in phosphate buffered saline (PBS) with 0.5 M 
glucose and incubated under sterile condition for 8 weeks at 37 °C. Reaction mixtures were dialyzed 
against PBS to remove free glucose and then passed through an affinity column (Pierce, Rockford, IL, 
USA) to remove any endotoxins. Non-glycated BSA was subjected to the same conditions with the 
exception of glucose as a control. AGEs were identified by fluorescence spectrophotometry [26]. 
3.3. RNA Interference 
The procedures used in this experiment were similar to those described in our previous report [27]. 
The following RAGE small interfering RNA (siRNA-RAGE) was synthesized by Invitrogen   
(Carlsbad, CA, USA): sense, 5'-GACCAACUCUCUCCUGUAUTT-3'; antisense, 
5'-AUACAGGAGAGAGUUGGUCTT-3'. A non-targeting siRNA duplex sequence (Invitrogen Stealth 
RNAi, Carlsbad, CA, USA) was used as a negative control. ECV304 cell transfection was performed 
according to the manufacturer’s instructions. Serum-starved ECV304 cells were subjected to AGEs and/or 
hyperoside for 10 min for Western blot analysis, or cultured for an additional 24 h for MTT assays. 
3.4. Cell Viability Assay (MTT) 
Cell viability was determined using a CellTiter 96 Non-Radioactive Cell Proliferation Assay kit 
(Promega, Madison, WI, USA) according to the manufacturer's instructions. Briefly, EVC304 cells were 
seeded in 96-well culture plates at 3000 cells/well. After incubation at 37 °C for 24 h, the medium was 
replaced with fresh medium supplemented either with or without hyperoside (50 μg/mL). After 
incubation for a further hour, AGEs (200 μg/mL) were added to the cells for 10 min. Dye solution was 
added to each well 24 h after treatment and the cells were incubated at 37 °C for 2 h. Solubilization/Stop 
Solution was added to each well and the absorbance was measured at 570 nm using an ELISA reader. 
Relative cell numbers were calculated after normalizing the absorbance to untreated cells. Cell viability 
was calculated relative to untreated cells. 
3.5. Knockdown of RAGE in ECV304 Cells 
An experimental system to study of the effects of RAGE on JNK activation in response to AGEs was 
established by transfecting quiescent ECV304 cells with siRNA-RAGE (100 pmol/well). The cells 
transfected were then treated with AGEs and/or hyperoside for 10 min. Lipofectamine 2000 and 
non-targeting siRNA were used as controls 
3.6. Western Blot Analysis 
Western blot analysis was performed as previously described [28], with minor modifications. Treated 
ECV304 cells were harvested in lysis buffer using protease inhibitors. The lysate suspension was 
centrifuged and protein concentration was assessed by Bio-Rad protein assay. Heat-denatured proteins 
were resolved by SDS-PAGE and electrophoretically transferred to nitrocellulose membranes.   Int. J. Mol. Sci. 2013, 14  22704 
 
The membranes were probed with antibodies against phosphorylated JNK (pJNK; Cell Signaling 
Technology, Danvers, MA, USA) and RAGE (R & D systems, Minneapolis, MN, USA) and reprobed 
with β-actin antibody (Cell Signaling Technology, Danvers, MA, USA). The bands were visualized 
using an enhanced chemiluminescence (ECL) detection system (GE Healthcare, Piscataway, NJ, USA). 
The intensities of the bands were quantified by densitometry. 
3.7. Real-Time qPCR  
qPCR was performed similar to those described previously[29]. In brief, it was performed with a 
Power SYBR Green PCR Master Mix (Takara, Dalian, China) on an ABI 7900 Real-time PCR 
instrument according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). 
The primer sequences used in this study were designed using Primer 3 (Whitehead Institute/MIT, 
Cambridge, MA, USA) and confirmed by BLAST in GenBank. Primers of qPCR for   
amplification of cDNA for RAGE and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 
synthesized by TaKaRa Biotechnology (Dalian, China) as follows: for GAPDH (228 bp) 
F-5'-CGACCACTTTGTCAAGC TCA-3', R-5'-AGGGGTCTACATGGCAACTG-3', for RAGE 
(143bp) F-5'-AGGAGCGTGCAG AACTGA AT-3', R-5'-GAGTTGGTCTGAGGCCAGAA-3'. 
3.8. Statistical Analysis 
Data from three independent experiments are expressed as mean ± SD. Statistical analyses were 
performed by one-way analysis of variance (ANOVA). p-values <0.05 were considered significant. 
Figure 5. Diagram showing the potential role of the RAGE signaling pathway in the actions 
of AGEs on JNK activation and ECV304 viability inhibition. Increased blood sugar 
(diabetes) can trigger rapid increases in AGEs on the walls of vein grafts and arteries. As the 
ligand of RAGE, AGEs can cause deformation of ECV304 cells, activating RAGE and its 
downstream signaling molecules, including JNK. Activated JNK (P-JNK) leads to 
overexpression of RAGE and viability inhibition of ECV304 cells (MTT), thereby altering 
vascular structure and function. Blocking RAGE and its downstream molecules by 
hyperoside might inhibit vascular remodeling induced by AGEs. 
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4. Conclusions 
This study has demonstrated a potential new mechanism for hyperoside in mediating the intracellular 
signaling pathways initiated by AGEs by inhibiting the effects of RAGE (Figure 5), thereby suppressing 
JNK activation and increasing cell proliferation in ECV304 cells. This suggests a novel role for 
hyperoside through blockade of the RAGE downstream signaling as a promising therapeutic method for 
preventing cardiovascular diseases. The findings may advance the current understanding of the effects 
of AGE on vascular remodeling and contribute to the study of vascular diseases and diabetes. 
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